Agenda-setting intelligence, analysis and advice for the global fashion community.
A new class of weight-loss drugs known as GLP-1s are proving to be game changers for people with obesity. They’re also minting billions for pharmaceutical companies, especially the companies that developed them, Eli Lilly & Co. and Novo Nordisk A/S. Yet the interest in these miracle drugs has presented some challenges. Not only are insurance companies sometimes balking at paying for the medications, which can cost as much as $16,000 a year, but ongoing shortages have created opportunities for lower-priced copycats. It also remains unclear whether pharma companies can actually deliver on the promise of even better weight-loss drugs — part of the premise behind their high stock prices. Another unknown variable is
Please sign in to ensure you can read our agenda-setting intelligence, analysis and advice. Or get in touch at support@businessoffashion.com if you experience difficulties.
